Vonaprument
Phase 3Active 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy
Conditions
Geographic Atrophy
Trial Timeline
Jul 30, 2024 → Oct 31, 2027
NCT ID
NCT06510816About Vonaprument
Vonaprument is a phase 3 stage product being developed by Annexon for Geographic Atrophy. The current trial status is active. This product is registered under clinical trial identifier NCT06510816. Target conditions include Geographic Atrophy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06510816 | Phase 3 | Active |
Competing Products
20 competing products in Geographic Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| avacincaptad pegol | Astellas Pharma | Phase 3 | 77 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 65 |
| avacincaptad pegol | Astellas Pharma | Approved | 85 |
| Avacincaptad pegol (ACP) | Astellas Pharma | Pre-clinical | 23 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 77 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 41 |
| FWY003 + Placebo | Novartis | Phase 2 | 52 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 52 |
| LFG316 + Sham + LFG316 Lower dose | Novartis | Phase 2 | 52 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 33 |
| RO7303359 | Roche | Phase 1 | 33 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 40 |
| Pozelimab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 49 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 74 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 18 |
| APL-2 + APL-2 | Apellis Pharmaceuticals | Phase 3 | 72 |